House passes spending bill that includes funding for the Children's Health Insurance Program for 6 years; researchers work on an experimental blood test that could detect 8 cancers; President Donald Trump plans to slash the budget of the Office of National Drug Control Policy by as much as 95%.
By a vote of 230 to 197, the House of Representatives passed a spending bill that would a government shutdown. According to The New York Times, the bill provides funding for the Children’s Health Insurance Program (CHIP) for 6 years. However, Senate Republicans are unlikely to sway enough Democratic votes. Democrats want more concessions as part of the spending bill, including a stronger government response to the opioid epidemic and protection for young immigrants brought to the country illegally when they were children.
A blood test in development might be able to detect 8 common cancers in the earliest stages, when those cancers are treatable. Researchers hope that the experimental test—which focuses on breast, colon, esophagus, liver, lung, ovarian, pancreas, and stomach cancers—will only cost $500, reported NPR. The researchers reported that, while the test was only successful 40% of the time in patients with stage 1 cancers, the finding still represents an important milestone in detecting cancers.
The budget of the Office of National Drug Control Policy could be cut by as much as 95%, according to plans from President Donald Trump. The office is responsible for coordinating the government’s response to the opioid crisis, according to Politico. The reduction in funding would mean moving the office’s 2 main grant programs to HHS and the Justice Department. The administration tried to eliminate those grant programs earlier, but received pushback from both parties.
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen